The hazard ratio (HR) for the primary endpoint was (3.84, p = 0.0009) in the first month The Prolocor pFCG™ test has the ...

CMS issued a final National Coverage Determination (NCD) that green-lights renal denervation (RDN) for uncontrolled ...

The preferred timing of treatment of nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) ...

A team of MIT engineers has designed a flexible drug-delivery patch that could help the heart heal after a heart attack.

Of note, the iMODERN trial had also excluded people with a history of prior STEMI, chronic total occlusion, complex ...

This page lists all known medications that could potentially lead to 'Myocardial infarction' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

Myocardial infarction (MI) can be recognized by clinical features, including electrocardiographic (ECG) findings, elevated values of biochemical markers (biomarkers) of myocardial necrosis, and by ...

PLASMA and serum enzyme-activity alterations have proved useful as laboratory parameters in the diagnosis of myocardial disease. 1 Among the enzymes employed to reflect myocardial necrosis are ...

Endogenous regeneration seen in animal models provides a template for optimal repair of the human heart following myocardial infarction. In the regenerating heart, new cardiomyocytes are produced by ...

The hazard ratio (HR) for the primary endpoint was (3.84, p = 0.0009) in the first monthThe Prolocor pFCG test has the potential to help providers reduce 30-day readmission rates for Acute MI, an impo ...